BioSyent (CVE:RX) Hits New 1-Year High – Should You Buy?
by Renee Jackson · The Cerbat GemBioSyent Inc. (CVE:RX – Get Free Report)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as C$13.40 and last traded at C$13.40, with a volume of 2422 shares changing hands. The stock had previously closed at C$13.30.
Wall Street Analyst Weigh In
Separately, Bloom Burton raised shares of BioSyent from a “moderate buy” rating to a “strong-buy” rating in a report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Strong Buy”.
Read Our Latest Analysis on BioSyent
BioSyent Trading Down 0.4%
The firm has a market cap of C$149.22 million, a P/E ratio of 17.71 and a beta of 0.55. The firm’s fifty day moving average is C$12.25 and its two-hundred day moving average is C$11.77. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.